Foghorn Therapeutics Inc

-0.38 (-4.82%)
Products, Regulatory

Foghorn Therapeutics Provides Update On FHD-286 Phase I Study In Relapsed/Refractory AML/MD

Published: 08/23/2022 13:00 GMT
Foghorn Therapeutics Inc (FHTX) - Foghorn Therapeutics Provides Further Update on Fhd-286 Phase I Study in Relapsed/refractory Aml/mds.
Foghorn Therapeutics Inc.- U.S. Food and Drug Administration (fda) Has Placed a Full Clinical Hold on Phase 1 Dose Escalation Study of Fhd-286.
Foghorn Therapeutics Inc.- Plans to Report Data From Mum Study in First Half of 2023.
Foghorn Therapeutics- Hold in Study Due to Observation of Additional Suspected Cases of Fatal Differentiation Syndrome Believed to Be Related to Fhd-286.